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Recent pathological and molecular studies have forced a
very significant re-evaluation of the conventional classifi-
cation of EOC. Microarray and other molecular experi-
ments demonstrate that EOC is a series of molecularly
distinct diseases that individually bear more resemblance
to certain non-ovarian cancers than they do to each
other. Ovarian cancer really represents a spectrum of
distinct diseases that share an anatomical location. The
presentation focuses on the increasing understanding of
the molecular differences between and within different
ovarian cancer histotypes. Particular attention is given
to high-grade ovarian serous cancers, which account for
about two thirds of ovarian cancer deaths, and ovarian
clear cell cancers, a tumour type with generally poor
response to platinum-based therapy.
Using both gene expression (GE) and DNA copy num-
ber (CN) analyses, we have defined novel molecular sub-
types of high-grade serous cancers [1]. The molecular
subtypes are robustly represented in multiple datasets
and are associated with distinct clinical outcomes, and
therefore appear to be biologically meaningful. Our
efforts to understand the drivers of molecular subtypes
of high-grade serous will be discussed [2,3]. A clear cell
cohort was analysed using GE and CN analyses, demon-
strating deregulation of receptor tyrosine kinases and
cytokine pathways [4]. In particular, deregulation of IL6/
STAT3/HIF pathway and its targeting in a clinical set-
ting will be described.
Platinum remains the mainstay of treatment for high-
grade serous cancers, however, about 20% of patients
fail initial treatment and of those that respond, the
majority relapse within 2 years and progressively
develop resistance to treatment. We have identified
mechanisms of primary treatment failure [5,6] and are
currently analysing paired primary and relapse samples
to determine mechanisms of acquired treatment failure
as part of the ICGC project. Studies in treatment resis-
tance will be discussed.
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